CEO Chris Kim's Valetudo Discloses 14.3% Stake, Revealing Massive Potential Dilution from InnocsAI Deal
LIMN is trading near its 52-week low of $0.095 (4.7% above the low) on light trading volume (0.1× avg).
Summary
CEO Chris Kim's Valetudo Therapeutics disclosed a 14.3% stake in Liminatus Pharma, including 3.45M common shares and preferred stock convertible into 489.8M shares—a potential dilution bomb that requires shareholder approval.
Key Events · Ownership and Investor Activity · LIMN
-
Valetudo Receives 3.45M Shares in InnocsAI Deal
Valetudo Therapeutics LLC, controlled by CEO Chris Kim, received 3,448,926 common shares as consideration in the InnocsAI acquisition, valued at approximately $343,000 at the current $0.0995 share price.
-
Preferred Stock Carries 489.8M Share Conversion Right
Valetudo also received 48,975 shares of Series A Non-Voting Convertible Preferred Stock, each convertible into 10,000 common shares—totaling 489,751,074 potential shares—but conversion requires stockholder approval under Nasdaq rules.
-
Potential Dilution Exceeds 7x Current Outstanding Shares
If fully converted, the preferred stock would add 489.8M shares to the current 67.2M outstanding, representing dilution of over 700% and dramatically reshaping the company's capital structure.
-
Voting Control Extended via Ewon Comfortech Agreement
Valetudo retains voting power over 4,373,603 shares transferred to Ewon Comfortech Co., Ltd on June 24, 2026, giving Kim effective control over 9.6M votes (14.3% of outstanding).
Analysis · LIMN · Life Sciences
As part of the InnocsAI acquisition, Valetudo Therapeutics—controlled by CEO Chris Kim—received 3.45 million common shares and 48,975 shares of Series A Preferred Stock. Each preferred share converts into 10,000 common shares, creating a potential 489.8 million shares, but only if shareholders approve the issuance. That represents over 7x the current outstanding shares, an enormous overhang. The filing also reveals that Valetudo controls voting for another 4.37 million shares held by Ewon Comfortech, cementing Kim's influence. With the stock at $0.0995 and a delisting fight underway, this disclosure quantifies just how dilutive the InnocsAI deal could become.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIMN was trading at $0.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.10 to $9.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.